Viridian Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases. The company's primary focus is on thyroid eye disease (TED), a rare and progressive autoimmune condition. Viridian is advancing multiple candidates targeting the insulin-like growth factor-1 receptor (IGF-1R). Its lead intravenous candidate, veligrotug (VRDN-001), has been granted Breakthrough Therapy Designation by the FDA and is under Priority Review. Additionally, the company is developing elegrobart (VRDN-003), a subcutaneously administered, half-life-extended monoclonal antibody designed for at-home self-administration via an autoinjector. Beyond its IGF-1R portfolio, Viridian is advancing preclinical and early-stage programs targeting thyroid-stimulating hormone receptor (TSHR) and neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out commercial infrastructure and establishing launch readiness in the U.S. to support the potential mid-2026 launch of veligrotug, which also lays the groundwork for future pipeline candidates.
Expected impact: Establishes Viridian's first commercial revenue stream and positions the company as a direct competitor in the multi-billion-dollar TED market.
Advancing elegrobart as a potential best-in-class subcutaneous anti-IGF-1R therapy delivered via a low-volume autoinjector for convenient self-administration at home.
Expected impact: Provides a highly differentiated, patient-friendly alternative to intravenous infusions, capturing market share from existing therapies.
Developing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, to address multiple autoimmune and neuromuscular diseases.
Expected impact: Diversifies the pipeline beyond thyroid eye disease into broader autoimmune indications.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides non-dilutive capital to fully fund the commercial launches of both veligrotug and elegrobart (VRDN-003).
Terms: Viridian received a $55 million upfront payment and is eligible for up to $115 million in near-term clinical and regulatory milestones, in exchange for tiered royalties on U.S. net sales of its TED franchise (7.5% up to $600M, 0.8% up to $900M, 0.25% up to $2B).
Expands the global reach of Viridian's lead assets by leveraging Kissei's established development and commercialization capabilities in Japan.
Terms: Viridian received a $70 million upfront cash payment and is eligible for up to $315 million in development, regulatory, and commercial milestones, plus tiered royalties on net sales in Japan ranging from the 20s to mid-30s percent.